Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proquazone is a nonsteroidal anti-inflammatory drug (NSAID) of the quinazolinone class, used primarily for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and other musculoskeletal disorders. It has also been trialed for acute pain states such as dysmenorrhea, postoperative pain, and headache. Unlike most NSAIDs, it does not have a free acid group in its structure. Its mechanism of action includes inhibition of cyclooxygenase enzymes (COX), leading to reduced synthesis of prostaglandins involved in inflammation and pain signaling[1][5]. Additionally, it inhibits core protein synthesis of proteoglycans and secondary biosynthesis of glycosaminoglycan chains in cartilage tissue[6][8]. Proquazone is considered comparable in efficacy to other NSAIDs but may cause gastrointestinal side effects such as diarrhea[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on proquazone.